{"id":8223,"date":"2025-04-16T14:52:04","date_gmt":"2025-04-16T06:52:04","guid":{"rendered":"https:\/\/regask.com\/?p=8223"},"modified":"2025-04-19T03:28:34","modified_gmt":"2025-04-18T19:28:34","slug":"riesgos-de-la-cadena-de-suministro-de-aranceles-biofarmaceuticos","status":"publish","type":"post","link":"https:\/\/regask.com\/es\/biopharma-tariff-supply-chain-risks\/","title":{"rendered":"El Departamento de Comercio de EE. UU. investiga posibles aranceles\u2026"},"content":{"rendered":"
<\/div>\n
\n
El 4 de abril de 2025, Fierce Pharma public\u00f3 un art\u00edculo que analiza el posible impacto de los aranceles del presidente Donald Trump en la industria biofarmac\u00e9utica. A pesar del reciente anuncio que exime del pago de aranceles a los productos farmac\u00e9uticos importados a EE. UU., existe una preocupaci\u00f3n constante en la industria por la posible imposici\u00f3n de aranceles a los medicamentos importados. David Ricks, director ejecutivo de Eli Lilly, comenta la situaci\u00f3n, destacando los desaf\u00edos y los posibles ajustes que las empresas podr\u00edan necesitar implementar en respuesta a estos aranceles. El objetivo principal de esta actualizaci\u00f3n es comprender las implicaciones del proteccionismo comercial para los costos de los medicamentos y la gesti\u00f3n de la cadena de suministro en el sector biofarmac\u00e9utico.<\/div>\n
\n
\n
    \n
  • El presidente Donald Trump ha considerado imponer aranceles \u201c25% o superiores\u201d a los medicamentos importados, aunque un anuncio reciente ha eximido temporalmente a los productos farmac\u00e9uticos de dichos aranceles.<\/li>\n
  • Eli Lilly ha invertido significativamente en la capacidad de producci\u00f3n estadounidense, pero tambi\u00e9n depende en gran medida de la fabricaci\u00f3n extranjera, especialmente en Irlanda. A la empresa le preocupa tener que absorber los costes arancelarios, lo que podr\u00eda conllevar reducciones de personal o de inversi\u00f3n en investigaci\u00f3n y desarrollo (I+D).<\/li>\n
  • El cronograma para implementar los aranceles sobre los medicamentos sigue siendo incierto, con un per\u00edodo m\u00e1ximo de investigaci\u00f3n de 270 d\u00edas mencionado en la Secci\u00f3n 232 de la Ley de Expansi\u00f3n Comercial.<\/li>\n
  • El primer ministro franc\u00e9s, Emmanuel Macron, critic\u00f3 los aranceles propuestos como \u201cbrutales e infundados\u201d e inst\u00f3 a los pa\u00edses europeos a suspender las inversiones en Estados Unidos hasta que se aclaren los detalles.<\/li>\n
  • Los analistas de UBS especulan que los productos farmac\u00e9uticos podr\u00edan eventualmente ser excluidos de un arancel base 10%, pero siguen siendo cautelosos sobre los posibles aranceles espec\u00edficos de la industria que podr\u00edan implementarse gradualmente.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n
    \n
    Evaluaci\u00f3n<\/span><\/div>\n
    \n
    \n

    Impacto:<\/strong>\u00a0Los aranceles propuestos podr\u00edan incrementar los costos operativos de las empresas biofarmac\u00e9uticas, en particular de aquellas que dependen de medicamentos o componentes importados. Esto podr\u00eda afectar el precio y la disponibilidad de los medicamentos, con posibles impactos en \u00e1reas terap\u00e9uticas que requieren medicamentos especializados o importados.<\/p>\n

    Pr\u00f3ximo:<\/strong>\u00a0Las empresas deben evaluar su cadena de suministro para detectar vulnerabilidades arancelarias y considerar aumentar la capacidad de producci\u00f3n nacional. Se recomienda promover pol\u00edticas comerciales claras y prepararse para posibles ajustes de costos en I+D y dotaci\u00f3n de personal. El enfoque debe centrarse en mantener el cumplimiento normativo y minimizar el impacto en los costos y la disponibilidad de los medicamentos.<\/p>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

    El 4 de abril de 2025, Fierce Pharma public\u00f3 un art\u00edculo que analiza el posible impacto de los aranceles del presidente Donald Trump en la industria biofarmac\u00e9utica. A pesar del reciente anuncio que exime del pago de aranceles a los productos farmac\u00e9uticos importados a EE. UU., existe una preocupaci\u00f3n constante en la industria sobre los futuros aranceles que podr\u00edan imponerse a los medicamentos importados. El director ejecutivo de Eli Lilly\u2026<\/p>","protected":false},"author":43,"featured_media":8224,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[527,35],"tags":[625],"class_list":["post-8223","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-united-states-regulations","category-pharma-biotech-latest-insights","tag-tariff-and-tax-regulations"],"acf":[],"yoast_head":"\nTrump Tariffs & Pharma: Supply Chain Risks? | RegASK<\/title>\n<meta name=\"description\" content=\"Trump's tariffs on biopharma: What's the impact on drug costs & your supply chain? Eli Lilly CEO weighs in. Key insights here.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/es\/riesgos-de-la-cadena-de-suministro-de-aranceles-biofarmaceuticos\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"US Department of Commerce Investigates Potential\u00a0Tariffs on Imported Pharmaceuticals Impacting Biopharma Industry Summary\" \/>\n<meta property=\"og:description\" content=\"Trump's tariffs on biopharma: What's the impact on drug costs & your supply chain? Eli Lilly CEO weighs in. Key insights here.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/es\/riesgos-de-la-cadena-de-suministro-de-aranceles-biofarmaceuticos\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-16T06:52:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-18T19:28:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2025\/04\/us-department-commerce-investigates-tariffs-imported-pharmaceuticals-biopharma-industry.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Reva Ananda\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Reva Ananda\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/biopharma-tariff-supply-chain-risks\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/biopharma-tariff-supply-chain-risks\\\/\"},\"author\":{\"name\":\"Reva Ananda\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\"},\"headline\":\"US Department of Commerce Investigates Potential\u00a0Tarif…\",\"datePublished\":\"2025-04-16T06:52:04+00:00\",\"dateModified\":\"2025-04-18T19:28:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/biopharma-tariff-supply-chain-risks\\\/\"},\"wordCount\":353,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/biopharma-tariff-supply-chain-risks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/us-department-commerce-investigates-tariffs-imported-pharmaceuticals-biopharma-industry.png\",\"keywords\":[\"tariff and tax regulations\"],\"articleSection\":[\"United States\",\"Pharma and Biotech\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/biopharma-tariff-supply-chain-risks\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/biopharma-tariff-supply-chain-risks\\\/\",\"name\":\"Trump Tariffs & Pharma: Supply Chain Risks? | RegASK\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/biopharma-tariff-supply-chain-risks\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/biopharma-tariff-supply-chain-risks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/us-department-commerce-investigates-tariffs-imported-pharmaceuticals-biopharma-industry.png\",\"datePublished\":\"2025-04-16T06:52:04+00:00\",\"dateModified\":\"2025-04-18T19:28:34+00:00\",\"description\":\"Trump's tariffs on biopharma: What's the impact on drug costs & your supply chain? Eli Lilly CEO weighs in. Key insights here.\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/biopharma-tariff-supply-chain-risks\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/regask.com\\\/biopharma-tariff-supply-chain-risks\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/us-department-commerce-investigates-tariffs-imported-pharmaceuticals-biopharma-industry.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/us-department-commerce-investigates-tariffs-imported-pharmaceuticals-biopharma-industry.png\",\"width\":800,\"height\":600,\"caption\":\"Us Department Commerce Investigates Tariffs Imported Pharmaceuticals Biopharma Industry\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\",\"name\":\"Reva Ananda\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Aranceles de Trump y la industria farmac\u00e9utica: \u00bfRiesgos en la cadena de suministro? | RegASK","description":"Aranceles de Trump a la biofarmac\u00e9utica: \u00bfCu\u00e1l es el impacto en los costos de los medicamentos y su cadena de suministro? El director ejecutivo de Eli Lilly opina. Ideas clave aqu\u00ed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/es\/riesgos-de-la-cadena-de-suministro-de-aranceles-biofarmaceuticos\/","og_locale":"es_ES","og_type":"article","og_title":"US Department of Commerce Investigates Potential\u00a0Tariffs on Imported Pharmaceuticals Impacting Biopharma Industry Summary","og_description":"Trump's tariffs on biopharma: What's the impact on drug costs & your supply chain? Eli Lilly CEO weighs in. Key insights here.","og_url":"https:\/\/regask.com\/es\/riesgos-de-la-cadena-de-suministro-de-aranceles-biofarmaceuticos\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2025-04-16T06:52:04+00:00","article_modified_time":"2025-04-18T19:28:34+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2025\/04\/us-department-commerce-investigates-tariffs-imported-pharmaceuticals-biopharma-industry.png","type":"image\/png"}],"author":"Reva Ananda","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Reva Ananda","Est. reading time":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/biopharma-tariff-supply-chain-risks\/#article","isPartOf":{"@id":"https:\/\/regask.com\/biopharma-tariff-supply-chain-risks\/"},"author":{"name":"Reva Ananda","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926"},"headline":"US Department of Commerce Investigates Potential\u00a0Tarif…","datePublished":"2025-04-16T06:52:04+00:00","dateModified":"2025-04-18T19:28:34+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/biopharma-tariff-supply-chain-risks\/"},"wordCount":353,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/biopharma-tariff-supply-chain-risks\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/04\/us-department-commerce-investigates-tariffs-imported-pharmaceuticals-biopharma-industry.png","keywords":["tariff and tax regulations"],"articleSection":["United States","Pharma and Biotech"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/regask.com\/biopharma-tariff-supply-chain-risks\/","url":"https:\/\/regask.com\/biopharma-tariff-supply-chain-risks\/","name":"Aranceles de Trump y la industria farmac\u00e9utica: \u00bfRiesgos en la cadena de suministro? | RegASK","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/biopharma-tariff-supply-chain-risks\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/biopharma-tariff-supply-chain-risks\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/04\/us-department-commerce-investigates-tariffs-imported-pharmaceuticals-biopharma-industry.png","datePublished":"2025-04-16T06:52:04+00:00","dateModified":"2025-04-18T19:28:34+00:00","description":"Aranceles de Trump a la biofarmac\u00e9utica: \u00bfCu\u00e1l es el impacto en los costos de los medicamentos y su cadena de suministro? El director ejecutivo de Eli Lilly opina. Ideas clave aqu\u00ed.","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/biopharma-tariff-supply-chain-risks\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/regask.com\/biopharma-tariff-supply-chain-risks\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2025\/04\/us-department-commerce-investigates-tariffs-imported-pharmaceuticals-biopharma-industry.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/04\/us-department-commerce-investigates-tariffs-imported-pharmaceuticals-biopharma-industry.png","width":800,"height":600,"caption":"Us Department Commerce Investigates Tariffs Imported Pharmaceuticals Biopharma Industry"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"El sistema operativo de IA regulatoria para equipos de alto rendimiento","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926","name":"Reva Ananda"}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/8223","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/users\/43"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/comments?post=8223"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/8223\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/media\/8224"}],"wp:attachment":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/media?parent=8223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/categories?post=8223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/tags?post=8223"}],"curies":[{"name":"Gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}